Pasithea Therapeutics Corp. (KTTAW) Net Cash Flow (2021 - 2026)

Pasithea Therapeutics has disclosed Net Cash Flow across 6 years of filings, most recently posting -$4.7 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 351.27% year-over-year to -$4.7 million; the TTM figure through Jun 2026 stood at $38.5 million (up 827.27% YoY), while the FY2025 annual figure was $48.3 million, up 613.71% from the prior year.
• Net Cash Flow came in at -$4.7 million for Q2 2026 at Pasithea Therapeutics, up from -$4.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $51.0 million in Q4 2025 to a low of -$7.0 million in Q3 2023.
• Average Net Cash Flow over 5 years is -$321378.0, with a median of -$3.2 million recorded in 2023.
• Year-over-year, Net Cash Flow plunged 360.45% in 2022 and surged 2168.64% in 2025.
• Over 5 years, Net Cash Flow stood at -$5.5 million in 2022, then surged by 41.39% to -$3.2 million in 2023, then increased by 23.87% to -$2.5 million in 2024, then surged by 2168.64% to $51.0 million in 2025, then sank by 109.21% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$4.7 million in Q2 2026, -$4.8 million in Q1 2026, and $51.0 million in Q4 2025.